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Abstract
Background: In genomic medical studies, one of the major objectives is to identify genomic factors with a
prognostic impact on time-to-event outcomes so as to provide new insights into the disease process. Selection
usually relies on statistical univariate indices based on the Cox model. Such model assumes proportional hazards
(PH) which is unlikely to hold for each genomic marker.
Methods: In this paper, we introduce a novel pseudo-R2 measure derived from a crossing hazards model and
designed for the selection of markers with crossing effects. The proposed index is related to the score statistic and
quantifies the extent of a genomic factor to separate patients according to their survival times and marker
measurements. We also show the importance of considering genomic markers with crossing effects as they
potentially reflect the complex interplay between markers belonging to the same pathway.
Results: Simulations show that our index is not affected by the censoring and the sample size of the study. It also
performs better than classical indices under the crossing hazards assumption. The practical use of our index is
illustrated in a lung cancer study. The use of the proposed pseudo-R2 allows the identification of cell-cycle
dependent genes not identified when relying on the PH assumption.
Conclusions: The proposed index is a novel and promising tool for selecting markers with crossing hazards effects.
Background
In genomic medical research, one of the major objec-
tives is to identify genomic markers having a prognostic
impact on clinical outcomes (e.g. relapse, death) so as to
provide new insights into the disease process. Most of
the studies which investigate the relationship between
genomic markers and time-to-event outcomes usually
rely on marginal survival analysis that consider univari-
ate prognostic indices derived from the semi-parametric
Cox proportional hazards model. This proportional
hazards (PH) assumption states that the ratio of the
hazard functions of different individuals remains con-
stant over time. Although this assumption is arbitrary, it
is widely used since it offers a convenient way to sum-
marize the effect of a covariate on the baseline hazard
function and the resulting inference on the parameters
of the model is robust enough to encompass some
instances of non-proportionality (monotone, converging
or diverging hazard functions). However, this PH
modelisation is clearly not coping with crossing hazard
functions. Crossing-hazards models explicitly specify
that there is a time at which the hazard curves for dif-
ferent levels of a covariate cross. To our best knowledge,
the crossing hazards phenomenon is barely investigated
in genomic studies and it is usually described as a time-
dependent effect of the genomic marker without any
meaningful bioclinical interpretation.
In this paper, we introduce a novel pseudo-R2 index
derived from a semi-parametric non-proportional
hazards model that is suited for the selection of genomic
markers with crossing hazard functions. We also discuss
one of the plausible interpretations for such crossing
phenomenon that relates to a gene effect modification.
For censored survival data, two main sapproaches have
been considered for quantifying the predictive ability of a
variable to separate patients: concordance and proportion
of explained variation. This latter quantifies the relative
gain in prediction ability between a covariate-based
model and a null model, by analogy with the well-known
linear model (and the R2 criterion). In this framework,
we propose a novel statistical quantity which is related to
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the score statistic. The proposed pseudo-R2 index relies
on the partial likelihood function in such a way that it
has an interpretation in terms of percentage of separabil-
ity between patients according to their survival times and
marker measurements. It extends a previous work [1] for
taking into account crossing hazards situations. From a
real example, we show that the proposed index can be
used to select genes with crossing hazards behavior that
potentially indicate a modification of their prognostic
effect. Moreover, it proves useful for identifying genomic
markers with a common effect across multiple genomic
studies due to its weak dependence on sample size varia-
tions. The paper is organized as follows. In section Meth-
ods, we first introduce an example of a simple interplay
between two markers (effect modification) that leads to
marginal crossing hazard functions and has prompted us
to derive a novel pseudo-R2 measure for such non-
proportional situations. Then, we introduce a semi-
parametric non-proportional hazards model which gives
rise to some crossing effect of the hazard function.
Finally, we derive from this model a pseudo-R2 measure
well-suited for crossing hazard function and show its link
to the robust score statistic for testing no effect of the
considered marker [2]. In the Results section, we report
and discuss the properties of the index from simulations
experiments and compare them to those of classical
indices [3-7] which are also linked to the likelihood func-
tion. In the Example section, we illustrate the use of the
index for selecting genomic factors with crossing hazard
effect in a lung cancer study. In the last section, we sum-
marize our work.
Methods
In this section, we first present a simple situation which
motivates the use of the semi-parametric non-propor-
tional hazards model introduced in the next subsection.
Notations
Let the random variables X and C be the failure and
censoring times, and T = min(X, C) be the observed fol-
low-up time. The random variables T and C are
assumed to satisfy the condition of independent censor-
ing [8]. We denote {Ni(t), t ≥ 0} the counting process
that indicates the number of events that have occurred
in the interval (0, t] for subject i, i = 1,..., n, so that Ni(t)
takes values 0 or 1. Let Yi be the at-risk process, so that
Yi(t) = 1 indicates that subject i is at risk just before
time t, and Yi(t) = 0 otherwise.
Let dNi(t) = Ni(t
- + dt) - Ni(t
-) be the number of
events occurring in the interval [t, t + dt) for subject i,
N¯(t) =
∑n
i=1
Ni(t) the total number of events that have
occurred in the interval (0, t] and Y¯(t) =
∑n
i=1
Yi(t) the
number of subjects at risk at time t. Finally, let Z
(g)
i
represent the value of the gth covariate for individual i.
Motivational situation: the modulating effect
In the following, we show how a simple interplay
between two binary markers Z(1) and Z(2) can lead to
marginal crossing hazard functions.
The joint distribution of Z(1) and Z(2) is defined by:
pjj′ = Pr{Z(1) = j; Z(2) = j′} (j, j′) ∈ {0, 1} × {0, 1}
It is assumed that the hazard function of subject i
with Z
(1)
i = j and Z
(2)
i = j
′ is given by
λ(t |Z(1)i = j; Z
(2)
i = j
′) = λ0(t) exp{(αj + γ )j′} (1)
where l0(t) is an arbitrary unspecified baseline hazard
function, and a and g are unknown regression
coefficients.
Model (1) describes a modulating effect of the two
markers Z(1) and Z(2), whereby Z(2) has a multiplicative
effect on the hazard and Z(1) has a multiplicative effect
only if Z(2) equals one (so called effect modification).
The corresponding hazard functions according to the
values of Z(1) and Z(2) are shown in Table 1.
Assuming that model (1) is the true one, the conse-
quences of omitting Z(2) on the formulation of the
observed hazards ratio relative to Z(1) is described
below. Expressing model (1) in terms of the conditional
survival function given (Z
(1)
i , Z
(2)
i ) leads to:
S(t |Z(1)i = j, Z
(2)
i = j
′) = S0(t)exp{(αj+γ )j
′}
where S0(t) is the survival function corresponding to
the baseline hazard function l0(t). The survival function
given (Z
(1)
i = j ) follows directly from Bayes’ theorem,
and the hazard function given (Z
(1)
i = j ) can be easily
deduced as:
λ(t |Z(1)i = j) = λ0(t)
[
S0(t)pj0 + e
αj+γ S0(t)
eαj+γ pj1
S0(t)pj0 + S0(t)
eαj+γ pj1
]
It is worth noting that this latter expression can be
obtained as the expectation of (1) taken over Z(2) given
Table 1 Hazard function
Z
(1)
Z
(2) 0 1
0 l0(t) l0(t)
1 l0(t)e
g l0(t)e
a+g
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the at risk process. Finally, the hazards ratio relative to
the values (Z
(1)
i = 1) and (Z
(1)
i = 0) is given by:
λ(t |Z(1)i = 1)
λ(t |Z(1)i = 0)
=
(
p11e
α+γ S0(t)
eα+γ + p10S0(t)
p11S0(t)
eα+γ + p10S0(t)
)
×
(
p01S0(t)
eγ + p00S0(t)
p01eγ S0(t)
eγ + p00S0(t)
) (2)
It appears from this expression that hazards may cross
over time. More precisely, it is shown in Additional File
1 that when a and g are positive and assuming a
balanced joint distribution for (Z(1), Z(2)), the hazards
ratio inverts at a given time in (0; +∞). Obviously, such
a time-dependence cannot be properly handled by using
the proportional hazards model to analyze the data.
Semi-parametric model
The proposed model defines the survival function of
subject i with covariate Zi as follows
Si(t |Zi) = exp
{
−
(∫ t
0
λ0(s)ds
)eβZi}
(3)
where l0(t) is an unspecified baseline hazard function
and b an unknown regression parameter. It is a particu-
lar case of a model that was proposed for handling
hazards ratio that invert over time [9], and it corre-
sponds to a semi-parametric generalization of the
Weibull distribution. For subject i; i = 1, ..., n, the
model (3) can be written in terms of the hazard function
λi(t |Zi) = λ0(t)eβZi0(t)(eβZi−1) (4)
where 0(t) =
∫ t
0
λ0(u)du is the cumulative baseline
cumulative hazard function.
In the simple case of a covariate Z taking values 0 or
1, the hazards ratio (HR) of the two groups correspond-
ing to Z = 1 and Z = 0 is equal to HR = eβ0(t)
(eβ−1) .
If b > 0, this function is increasing from 0 to +∞ and
takes value 1 for τ = −10
[
exp(− β
eβ − 1)
]
. In this case,
the risk of occurrence of the event is smaller in group 1
than in group 0 for 0 ≤ t < τ, and becomes greater when
t > τ. If b < 0, the hazards ratio is decreasing from +∞
to 0 and takes value 1 for t = τ as calculated above. The
risk of occurrence of the event is thus greater in group
1 than in group 0 when 0 <t ≤ τ and becomes smaller
for t > τ.
Thus, as expected, model (4) allows hazards to cross
over time. Note that the survival functions cross at a
time larger than the crossing time of the hazards, and
may not cross at a finite time.
At time t and for an individual i, i = 1, ..., n, the first
derivative of the partial log-likelihood with respect to b
is the score function:
U(β ; t) =
n∑
i=1
[∫ t
0
Zi
(
1 + eβZi log{0(s)}
)
−
∑n
l=1 Yl(s)Zl0(s)
(eβZl−1)(1 + log{0(s)})∑n
l=1 Yl(s)e
βZl0(s)
(eβZl−1)
]
dNi(s)
The score function evaluated for b = 0 can be written
at time t as
U(0; t) =
n∑
i=1
Ui(0; t)
=
n∑
i=1
∫ t
0
[
Ziω(s) −
∑n
l=1 Yl(s)Zlω(s)∑n
l=1 Yl(s)
]
dNi(s)
(5)
with ω(s) = 1 + log{Λ0(s)}.
Pseudo-R2 measure
The goal of this section is to propose a pseudo-R2 index
that can be interpreted in terms of percentage of separ-
ability between patients according to their survival times
and marker measurements under the crossing hazards
model (4). The approach used below is based on the
score function (5). It extends the particular case that we
considered in a former work [1] where we assumed the
classical PH model. The main idea is to note that the
score can be rewritten as a separability quantity between
patients experiencing or not the event of interest. More
precisely, the quantities Ui in (5) can be rewritten as
Ui(0; t) =
∫ t
0
[(
Zi −
∑n
l=1;l=i Yl(s)Zl
Y¯(s) − 1
)]
ω∗(s)dNi(s)
With ω∗(s) = ω(s) × Y¯(s) − 1
Y¯(s)
.
From this expression, we show that, for a given covari-
ate Z at time t, the Ui can be expressed as the weighted
difference between the value of the covariate of the
patient observed to experience the event of interest and
the mean of the covariates of the group of patients
observed to not experience the event.
An estimation of the Ui is given by
Uˆi = δiωˆ(ti)
(
Zi −
∑
n
l=1 Yl(ti)Zl∑n
l=1 Yl(ti)
)
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where ωˆ (ti) = (1 + log{ˆ0(ti)}) , Λ0(ti) is estimated by
the left-continuous version of the Nelson’s estimator
[10,11], and δi, i = 1, ..., n is the indicator of failure at
time ti.
For distributional reason, instead of the Ui, we introduce
the so called robust scores Wi [2] which expressions are
Wi(0; t) =
∫ t
0
[
Zi − s
(0)(t)
s(1)(t)
]
ω(s)dNi(s) (6)
Where
s(r)(t) = E[S(r)(t)], r = 0, 1
S(0)(t) =
n∑
l=1
Yi(t)
S(1)(t) =
n∑
i=1
Yi(t)Zi
The Wi can be estimated by
Wˆi = δiωˆ(ti)
⎛
⎜⎜⎝Zi −
n∑
l=1
Yl(ti)Zl
n∑
l=1
Yl(ti)
⎞
⎟⎟
−
n∑
l=1
δlωˆ(tl)Yi(tl)
n∑
r=1
Yr(tl)
⎛
⎜⎜⎝Zi −
n∑
r=1
Yr(tl)Zr
n∑
r=1
Yr(ti)
⎞
⎟⎟
(7)
The sum over i of the robust Wi, i = 1, ..., n is identi-
cal to the sum of the Ui. However, as for the Cox
model, the Wi are independent, while the Ui are not.
Finally, the index is equal to the robust score statistic
divided by the number of distinct uncensored failure
times k:
D0 =
1
k
(
k∑
i=1
Wˆi
)2
k∑
i=1
Wˆ2i
=
1
k
(
k∑
i=1
Uˆi
)2
k∑
i=1
Wˆ2i
The index D0 is interpreted in terms of percentage of
separability over time between the event/non-event
groups. Its calculation is easy as it does not require the
estimation of the parameter b of the crossing hazards
model. We can easily demonstrate that 0 ≤ D0 ≤ 1.
It is worth noting that the index D0 can be interpreted
as a pseudo-R2 measure. In the linear regression model,
the R2 (coefficient of determination) can be directly
linked to likelihood-related quantities such as the Wald
test, the likelihood ratio and the score statistics (see
[12]). These formal relationships provide different ways
to interpret the R2. In the framework of non-linear
models, statisticians have searched for a corresponding
index and different pseudo-R2 statistics have been pro-
posed for censored data. Our proposed index is an
extension of the definition of the R2 for survival model
with crossing hazards which relies on the score statistic.
Results
Simulation Scheme
A simulation study was performed to describe the beha-
vior of the proposed index, D
(NPH)
0
, in finite samples
generated under the crossing hazards model (3), and to
compare it to the behavior of other existing indices. Dif-
ferent situations were considered, corresponding to dif-
ferent covariate distributions, regression parameter
values and sample sizes. The influence of various cen-
soring distributions was also investigated. The indices
that were compared to D
(NPH)
0
include our previous
index derived from a PH model (i.e. calculated accord-
ing to the same approach than D
(NPH)
0
with ω(ti) = 1,
[1]) and other most usual indices: Allison’s index [3], its
modified version [5], Nagelkerke [4] and Xu and
O’Quigley’s [6] indices. All of them are designed for a
PH model and are denoted D
(PH)
0
, ρ2N,ρ
2
k , R
2
N and
ρ2XOQ , respectively. The different elements defining a
configuration were the following. For a given subject,
the distribution of the covariate Z included in model (3)
was either discrete (Bernoulli ℬ(0.5)) or continuous
(log-normal with mean 0 and variance 1/4, or uniform
U[0,
√
3]) . These three distributions of Z were standar-
dized to have the same variance. Two distributions for
the survival time X were considered. The first one was
defined by model (3) with Λ0(t) = t. It is equivalent to a
Weibull parametric model W(η,α) with scale para-
meter h = 1 and shape parameter a = exp(bZ). The sec-
ond one correspond to a log-normal distribution with
mean equal to 0 and standard deviation equal to e-bZ.
These two distributions allowed to simulate the crossing
hazards phenomenon.
The coefficient b was given a value such that eb = 1, or
2, or 3, or 4. It can be noticed that, in the case of a Ber-
noulli variable Z, the hazard functions corresponding to eb
= 2, or 3, or 4 cross when the survival function of group Z
= 1 equal 0.78, 0.82, 0.85 respectively. The censoring vari-
able Ci was assumed to be independent from Xi given Zi
and distributed according to either a uniform
Ci ∼ U{0, r} or exponential Ci ~ℰ(g) distribution. The
parameters r and g were calculated in order to yield an
expected overall percentage of censoring pc equal to 0%,
25% and 50%. The sample size n was taken equal to 50,
100 or 500. Data were generated as follows. For each
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subject i, i = 1, ..., n, a value of the covariate Zi was gener-
ated. Given that value, a survival time Xi was generated
according to a either Weibull distribution
W(η = 1,α = eβZi) , or a log-normal distribution
LogN (μ = 0, σ 2 = e−2βZi ) . The censoring variable Ci was
independently generated and the observed follow-up time
Ti was calculated as min(Xi, Ci). For each configuration
1,000 independent replications were generated.
Simulation Results
Figures 1, 2 and 3 display the results of the simulations
obtained for D
(NPH)
0
, D
(PH)
0
, ρ2N,ρ
2
k , R
2
N and ρ
2
XOQ for
n = 100, for a Bernoulli, a uniform and a log-normal
distribution, respectively, according to the values of eb
and the percentage of censoring pc. Figures 4, 5 and 6
give the results for n = 50. The results for n = 500 are
given in Additional Files 2, 3 and 4.
As seen from Figures 1, 2, 3, 4, 5 and 6 and Addi-
tional Files 2, 3 and 4, when b = 0, i.e. in the absence of
covariates, the different indices are close to zero for n =
50, 100 and 500. Among the six indices, only D
(NPH)
0
shows a mean value increasing regularly with b. The
means of the five other indices do not appear to
increase with b and remain below 0.05 even for the
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Figure 1 Simulations results for D
(NPH)
0
, D
(PH)
0
, ρ2N,ρ
2
k ,R
2
N and ρ
2
XOQ , for n = 100 subjects, Z ∼ B(1/2), X ∼ W(1, eβZ) and a
uniform censoring (1,000 repetitions). Boxplots of the different indices according to the values of eb and pc.
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highest value of eb = 4. When b ≠ 0, the mean values of
D
(NPH)
0
for the different sample sizes are fairly stable.
The standard errors of the six indices are small when
b = 0. The standard errors of D
(NPH)
0
are larger than
those of the other indices when b ≠ 0 and slightly
decrease as b increases. As expected, the standard errors
of the different indices decrease when n increases.
The mean value of D
(NPH)
0
does not appear to be sen-
sitive to the censoring rate. However, the standard error
of this index moderately increases as the percentage of
censoring increases from 0% to 50%. In addition, the
results obtained with a log-normal distribution of the
survival time X on one hand (see Additional Files 5, 6
and 7 for the case n = 100), and with an exponential
distribution of the censoring variable, on the other hand
(not shown) are very similar, concerning D
(NPH)
0
and
the other indices as well.
Application of the index on real data
In this section, we illustrate the use of the proposed
index by selecting transcriptomic prognostic factors
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having a crossing effect in a lung cancer study. We
compare the selection to the one obtained when relying
on the index calculated under a proportional hazards
model.
Dataset
This series is composed of 74 patients who underwent
surgery at the Hôtel-Dieu Hospital (AP-HP, France)
between August 2000 and February 2004 for stage IB
(pT2N0) primary adenocarcinoma or large cell lung car-
cinoma of peripheral location [13]. Relapse-free survival
was defined as the time from surgery until disease-
related death, disease recurrence (either local or distant),
or last follow-up examination. The median relapse-free
survival time was 63.8 months. The two years relapse-
free survival was 80.3%[71.2%, 90.5%], and the five years
relapse-free survival was 59.3%[47.2%, 74.5%]. For each
patient, we considered the gene expression measurments
of 51,852 transcripts (obtained using Aymetrix HU133
Plus 2.0; Aymetrix, Santa Clara, CA, USA) located on
the autosomal chromosomes.
Selection of the variables
The genes were ranked according to the value of either
D
(NPH)
0
or D(PH)0 . We decided to focus our attention on
the first 200 top-ranked transcripts in both cases. The
lowest separability for both indices were close to each
other (29.8% for D
(NPH)
0
and 29.1% for D
(PH)
0
). Only a
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small proportion of transcripts (5%) was common to
both lists.
We then examined the biological processes that were
significantly over-represented in the two sublists using
the PANTHER (Protein ANalysis THrough Evolutionary
Relationships) classification system [14]. Results showed
that the two indices allow selecting genes involved in
different biological processes (See Additional File 8). For
the cell-cycle process, D(NPH)0 selected 25 transcripts
(significantly higher number than the 5% expected by
chance), whereas D
(PH)
0
selected only 16 transcripts
(not significantly higher number than the 5% expected
by chance). The two lists of genes involved in cell cycle
are given in Additional File 9.
Among the 25 cell-cycle related transcripts selected
according to D
(NPH)
0
, we discussed the behavior of two
genes, namely FGFR2, MCL1, known to be involved in
complex biological pathways. In particular, we examined
whether the crossing phenomenon (observed om Figures
7.a and 7.b) could potentially be related to some effect
modification of other genes.
The gene FGFR2 (fibroblast growth factor receptor 2)
is known to be involved in various cancer types [15] and
low gene expression measurements have been reported
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Figure 4 Simulations results for D
(NPH)
0
, D
(PH)
0
, ρ2N,ρ
2
k ,R
2
N and ρ
2
XOQ , for n = 50 subjects, Z ∼ B(1/2), X ∼ W(1, eβZ) and a
uniform censoring (1,000 repetitions). Boxplots of the different indices according to the values of eb and pc.
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as linked to a shorter survival in lung cancer [16]. The
analysis of FGFR2 gene expression taking into account
FGF4 gene expression, which is one of its ligand, sug-
gested a potential modulating effect between the two
genes. In the following, we reported the hazards ratio
(HR) computed under the Cox PH model for the four
groups resulting from dichotomizing the two variables
at the median. We also displayed the Kaplan-Meier
curves on Figure 7.c. As seen on this latter, patients
with low expression (below the median) of both FGFR2
and FGF4 have the worst prognosis (reference group).
When FGFR2 is highly expressed (above the median)
and FGF4 lowly expressed, the survival is not signifi-
cantly improved (HR = 0.532 [0.202, 1.399]). However,
the over-expression of FGF4 significantly improve the
survival (HR = 0.329 [0.112, 0.967]). Finally, patients
with a high expression of FGFR2 and FGF4 have the
best prognosis (HR = 0.103 [0.021, 0.516]).
In the same way, we discussed the interaction between
MCL1 and BCL2, two anti-apoptotic genes belonging to
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uniform censoring (1,000 repetitions). Boxplots of the different indices according to the values of eb and pc.
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the BCL-2 gene family. Considered initially as onco-
genes, the prognostic impact of BCL-2/MCL-1 for var-
ious type of cancer is debated due to their dual function
on cell death and cell proliferation (for a review, [17]).
The anti-apoptotic effect is associated with resistance to
chemotherapy, leading an adverse prognostic role in
some cancers such as leukemia or advanced ovarian
tumors. In contrast, the anti-proliferative activity of
MCL-1 and BCL-2 is associated with a favorable prog-
nosis effect in some early carcinomas, such as lung
adenocarcinoma [18]. Moreover, the combined analysis
of MCL1 and BCL2 gene expressions indicated a poten-
tial modulating effect between them. As seen on Figure
7.d., in our lung cancer study of early lung adenocarci-
nomas treated by surgery alone, patients with low
expression (below the median) of both genes MCL1 and
BCL2 have the worst prognosis (reference group). When
MCL1 is highly expressed (above the median) and BCL2
lowly expressed, the prognosis is not significantly
improved (HR = 0.533[0.202, 1.4103]). On the contrary,
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Figure 6 Simulations results for D
(NPH)
0
, D
(PH)
0
, ρ2N,ρ
2
k ,R
2
N
and ρ2XOQ , for n = 50 subjects, Z ∼ LogN (0; 1/4), X ∼ W(1, eβZ) and a
uniform censoring (1,000 repetitions). Boxplots of the different indices according to the values of eb and pc.
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patients with low expression of MCL1 and high expres-
sion of BCL2 have a significantly improved survival (HR
= 0.296[0.091, 0.962]). Finally, the over-expression of
both MCL1 and BCL2 gives the best prognosis (HR =
0.189[0.051, 0.700]).
In these two examples, we could hypothesize that the
crossing effect observed in the marginal analysis of FGFR2
or MCL1 is related to some potential effect modification
linked to FGF4 or BLC2, respectively. This hypothesis is
consistent with the known biological activity of those
genes. FGFR2 encodes for a receptor, which needs one of
its ligand (i.e. FGF4 ) for activation and biological activity.
Also, BCL2 and MCL-1 encode two proteins of the same
family, which may act together on the cell through hetero-
dimerization on apoptosis or cell proliferation. The result-
ing subgroup of patients defined by high expression of
these genes couples might be clinically relevant and the
object of further investigations.
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Discussion
For survival data analysis, univariate feature selection
strategy is mainly based on ranking markers according
to the value of a test statistic or a predictive index
obtained under the classical Cox PH model. In such set-
ting, we demonstrated in a previous work the interest of
using a pseudo-R2 measure for genomic studies. How-
ever, various departures from the PH assumption can be
observed and crossing hazards phenomenon can be
encountered in real situations.
In this context, we propose a novel pseudo-R2 mea-
sure that is suitable for identifying genomic markers
with crossing effects. It is linked to a semi-parametric
survival model that provides sufficient flexibility to
handle data with crossing hazards. Selecting such mar-
kers is potentially important since it could reflect the
complex interplay between genes belonging to the
same pathway.
The proposed index is ranging from zero to one and
can be interpreted in terms of percentage of separability
over time between the subgroup of subject(s) experien-
cing the event and the subgroup of those experiencing
the event at a later time. It quantifies the prognostic
separability of markers under a crossing hazard function
assumption, whereas for the proportional hazards setting
other specialized indices have previously been proposed
[1]. This pseudo-R2 is derived from the partial log-likeli-
hood function and directly linked to the robust score
statistic, while similar derivations from Wald or likeli-
hood ratio statistics are not trivial and not easily tract-
able. As seen from our simulation results, the proposed
index increases with the value of the regression para-
meter and is affected neither by the percentage of cen-
soring nor the sample size of the study. The results
show that our pseudo-R2 is the most suitable for taking
into account the crossing hazards phenomenon, as com-
pared to classical indices.
From a real dataset on lung cancer, we show that our
index allows to identify genes involved in biological pro-
cesses linked to the tumor evolution and that are not
selected under the PH assumption.
Among the cell-cycle related genes of our selection,
we investigate two genes, FGFR2 and MCL1, which
crossing effects could potentially be linked to some
modulating effect due to other genes from the same bio-
logical pathway. Knowing the complexity of gene inter-
actions, this is an over-simplification of the biological
reality and other mechanisms can obviously lead to such
non-proportional phenomenon. In this analysis, the
gene expression measurements are dichotomized based
on the median but other cutoffs could be investigated
(by searching for optimal cutoff point) as proposed by
Motakis et al. [19]. To the best of our knowledge, the
present work is the first to propose a pseudo-R2 mea-
sure that is specifically designed for crossing hazards
situations.
Conclusions
We propose a novel pseudo-R2 measure that quantifies
the prognostic separability of markers under a crossing
hazard function assumption. This phenomenon can be
encountered in real situations promoting the use of this
novel index.
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